Does Dr. KHALED ABDUL-NOUR have financial conflicts of interest?

Dr. KHALED ABDUL-NOUR (M.D.) has received a total of $11,754 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $9,621 in personal promotional payouts (consulting, meals, travel) and $2,132 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. KHALED ABDUL-NOUR?

According to CMS Open Payments data, Dr. KHALED ABDUL-NOUR received funding from SIEMENS MEDICAL SOLUTIONS USA ($9,225), NOVARTIS PHARMACEUTICALS CORPORATION ($1,807), and ELI LILLY AND COMPANY ($325).

Does Dr. KHALED ABDUL-NOUR receive research grants or speaking fees?

Dr. KHALED ABDUL-NOUR has received $9,621 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $2,132 in clinical research grants.

DR. KHALED ABDUL-NOUR

M.D.Real-Time Hydrated

Specialty: Internal Medicine, Cardiovascular Disease

Practice Location: DETROIT, MI 48202

NPI Number: 1184792608

LIFETIME INDUSTRY VALUE

$11,754

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABDUL-NOUR is a verified Internal Medicine, Cardiovascular Disease practitioner based in DETROIT, MI.

Between 2021 and 2024, Dr. ABDUL-NOUR had an overall industry promotional and research financial footprint of $11,754 as recorded in the federal CMS Open Payments database.

$9,621 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$2,132 was allocated to sponsored clinical trials and medical research activities.

Dr. ABDUL-NOUR's primary funding source is SIEMENS MEDICAL SOLUTIONS USA, which accounts for $9,225 (representing 78.5% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

SIEMENS MEDICAL SOLUTIONS USA

Rank 1

$9,225

78.5%

NOVARTIS PHARMACEUTICALS CORPORATION

Rank 2

$1,807

15.4%

ELI LILLY AND COMPANY

Rank 3

$325

2.8%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.